Lu 177 Psma clinical trials

Explore recruiting lu 177 psma clinical trials.

Recruiting lu 177 psma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Lu 177 Psma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

DUET-study: A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AFTER CURATIVE THERAPY.

Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Lu 177 Psma trials by city

Lu 177 Psma in Toronto Lu 177 Psma in Vancouver Lu 177 Psma in Montreal Lu 177 Psma in Calgary Lu 177 Psma in Edmonton Lu 177 Psma in Ottawa Lu 177 Psma in Winnipeg Lu 177 Psma in Quebec City Lu 177 Psma in Hamilton Lu 177 Psma in Kitchener Lu 177 Psma in London Lu 177 Psma in Halifax Lu 177 Psma in New York Lu 177 Psma in Los Angeles Lu 177 Psma in Chicago Lu 177 Psma in Houston

Lu 177 Psma clinical trials

Recruiting lu 177 psma studies right now

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

PSMA-RLT in Biochemically Recurrent PCa

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Dynamic 68Ga-PSMA and 18F-FDG PET/CT Analysis Prior to 177Lu-PSMA

Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617

Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Also recruiting in Europe

DUET-study: A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AFTER CURATIVE THERAPY.

Lu 177 Psma trials by city

Other conditions